Monitoring of serum HBV RNA, HBcrAg, HBsAg and anti-HBc levels in patients during long-term nucleoside/nucleotide analogue therapy
This study was aimed at evaluating the clinical significance of serum HBV RNA, hepatitis B core-related antigen (HBcrAg) and hepatitis B core antibody (anti-HBc) levels in chronic hepatitis B patients with undetectable HBV DNA during nucleoside/nucleotide analogue (NA) treatment. Fifty-seven patient...
Gespeichert in:
| Veröffentlicht in: | Antiviral therapy 2019-01, Vol.24 (2), p.105-115 |
|---|---|
| Hauptverfasser: | , , , , , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 115 |
|---|---|
| container_issue | 2 |
| container_start_page | 105 |
| container_title | Antiviral therapy |
| container_volume | 24 |
| creator | Liao, Hao Liu, Yan Li, Xiaodong Wang, Jie Chen, Xiangmei Zou, Jun Li, Qi Liu, Lujie Wang, Jun Huang, Bixia Lu, Fengmin Xu, Dongping |
| description | This study was aimed at evaluating the clinical significance of serum HBV RNA, hepatitis B core-related antigen (HBcrAg) and hepatitis B core antibody (anti-HBc) levels in chronic hepatitis B patients with undetectable HBV DNA during nucleoside/nucleotide analogue (NA) treatment.
Fifty-seven patients who received long-term NA treatment of median 5.83 (25%, 75% percentiles 4.67, 7.75) years were enrolled, and 285 serum samples at five time points for each patient were quantitatively analysed for the three serum markers together with serum HBV DNA and hepatitis B surface antigen (HBsAg) levels.
The HBV RNA level significantly correlated with HBcrAg (r=0.629; P |
| doi_str_mv | 10.3851/IMP3280 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_2149862079</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>2241327633</sourcerecordid><originalsourceid>FETCH-LOGICAL-c309t-854a1b601b84fa8dda66357b365dd74d70f915d006bf297abc3a815ccdd0ff953</originalsourceid><addsrcrecordid>eNpdkctKxDAUhoMoOl7wDSTgQhdWT5KmTZbj4A28Ieq2pE1aK20zJqng1ic3OqMLF4fzc_j4OPAjtEvgmAlOTq5u7hkVsIImFFJIKHCxiiaEcZlknPENtOn9KwAVEmAdbTDghMiUTNDnjR3aYF07NNjW2Bs39vjy9Bk_3E6PYqjctPneftpgNeg4oU3iGXfm3XQetwOeq9CaIXisxx9NZ4cmCcb1eBirzljfanOyiCHGqFCdbUaDw4txav6xjdZq1Xmzs9xb6On87HF2mVzfXVzNptdJxUCGRPBUkTIDUoq0VkJrlWWM5yXLuNZ5qnOoJeEaICtrKnNVVkwJwqtKa6hrydkWOlx4586-jcaHom99ZbpODcaOvqAklSKjkMuI7v9DX-3o4t-RoilhNM8Yi9TBgqqc9d6Zupi7tlfuoyBQfNdSLGuJ5N7SN5a90X_cbw_sC0JLhpw</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2241327633</pqid></control><display><type>article</type><title>Monitoring of serum HBV RNA, HBcrAg, HBsAg and anti-HBc levels in patients during long-term nucleoside/nucleotide analogue therapy</title><source>MEDLINE</source><source>Sage Journals GOLD Open Access 2024</source><source>Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals</source><creator>Liao, Hao ; Liu, Yan ; Li, Xiaodong ; Wang, Jie ; Chen, Xiangmei ; Zou, Jun ; Li, Qi ; Liu, Lujie ; Wang, Jun ; Huang, Bixia ; Lu, Fengmin ; Xu, Dongping</creator><creatorcontrib>Liao, Hao ; Liu, Yan ; Li, Xiaodong ; Wang, Jie ; Chen, Xiangmei ; Zou, Jun ; Li, Qi ; Liu, Lujie ; Wang, Jun ; Huang, Bixia ; Lu, Fengmin ; Xu, Dongping</creatorcontrib><description>This study was aimed at evaluating the clinical significance of serum HBV RNA, hepatitis B core-related antigen (HBcrAg) and hepatitis B core antibody (anti-HBc) levels in chronic hepatitis B patients with undetectable HBV DNA during nucleoside/nucleotide analogue (NA) treatment.
Fifty-seven patients who received long-term NA treatment of median 5.83 (25%, 75% percentiles 4.67, 7.75) years were enrolled, and 285 serum samples at five time points for each patient were quantitatively analysed for the three serum markers together with serum HBV DNA and hepatitis B surface antigen (HBsAg) levels.
The HBV RNA level significantly correlated with HBcrAg (r=0.629; P<0.001) but not HBsAg levels (P=0.1460). Nonetheless, the HBcrAg level significantly correlated with the HBsAg level (r=0.469; P<0.001). Hepatitis B e antigen (HBeAg)-positive samples showed higher HBV RNA, HBcrAg and HBsAg levels than HBeAg-negative samples did (all P<0.05). Nine patients with HBeAg loss manifested a significantly greater decline in HBV RNA and HBcrAg levels (median 1.84 [25%, 75% percentiles 1.02, 2.12] log
copies/ml, 1.14 [0.62, 2.21] log
U/ml, respectively) compared with those in seven patients without HBeAg loss (0.74 [0.10, 1.08] log
copies/ml and 0.41 [0.21, 0.69] log
U/ml, respectively). Overall, serum HBV RNA, HBcrAg, HBsAg and anti-HBc levels gradually decreased with time during NA treatment. At the end of observation, HBV RNA and HBcrAg reached an undetectable level in 26 and 6 (46% and 11%) patients, respectively.
Monitoring of HBV RNA and HBcrAg levels is useful for NA-treated patients with undetectable HBV DNA. The attainment of HBV RNA undetectability usually occurs prior to HBcrAg undetectability.</description><identifier>ISSN: 1359-6535</identifier><identifier>EISSN: 2040-2058</identifier><identifier>DOI: 10.3851/IMP3280</identifier><identifier>PMID: 30511941</identifier><language>eng</language><publisher>England: International Medical Press</publisher><subject>Adult ; Antigens ; Antiviral Agents - therapeutic use ; Biomarkers ; Deoxyribonucleic acid ; DNA ; Female ; Hepatitis ; Hepatitis B Antibodies - blood ; Hepatitis B Antibodies - immunology ; Hepatitis B Core Antigens - blood ; Hepatitis B e antigen ; Hepatitis B surface antigen ; Hepatitis B Surface Antigens - blood ; Hepatitis B virus - immunology ; Hepatitis B, Chronic - blood ; Hepatitis B, Chronic - diagnosis ; Hepatitis B, Chronic - drug therapy ; Hepatitis B, Chronic - virology ; Humans ; Interferon ; Male ; Middle Aged ; Nucleoside analogs ; Nucleotide analogs ; Patients ; Ribonucleic acid ; RNA ; RNA, Viral ; Treatment Outcome ; Viral Load</subject><ispartof>Antiviral therapy, 2019-01, Vol.24 (2), p.105-115</ispartof><rights>Copyright International Medical Press 2019</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c309t-854a1b601b84fa8dda66357b365dd74d70f915d006bf297abc3a815ccdd0ff953</citedby><cites>FETCH-LOGICAL-c309t-854a1b601b84fa8dda66357b365dd74d70f915d006bf297abc3a815ccdd0ff953</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,776,780,27901,27902</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/30511941$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Liao, Hao</creatorcontrib><creatorcontrib>Liu, Yan</creatorcontrib><creatorcontrib>Li, Xiaodong</creatorcontrib><creatorcontrib>Wang, Jie</creatorcontrib><creatorcontrib>Chen, Xiangmei</creatorcontrib><creatorcontrib>Zou, Jun</creatorcontrib><creatorcontrib>Li, Qi</creatorcontrib><creatorcontrib>Liu, Lujie</creatorcontrib><creatorcontrib>Wang, Jun</creatorcontrib><creatorcontrib>Huang, Bixia</creatorcontrib><creatorcontrib>Lu, Fengmin</creatorcontrib><creatorcontrib>Xu, Dongping</creatorcontrib><title>Monitoring of serum HBV RNA, HBcrAg, HBsAg and anti-HBc levels in patients during long-term nucleoside/nucleotide analogue therapy</title><title>Antiviral therapy</title><addtitle>Antivir Ther</addtitle><description>This study was aimed at evaluating the clinical significance of serum HBV RNA, hepatitis B core-related antigen (HBcrAg) and hepatitis B core antibody (anti-HBc) levels in chronic hepatitis B patients with undetectable HBV DNA during nucleoside/nucleotide analogue (NA) treatment.
Fifty-seven patients who received long-term NA treatment of median 5.83 (25%, 75% percentiles 4.67, 7.75) years were enrolled, and 285 serum samples at five time points for each patient were quantitatively analysed for the three serum markers together with serum HBV DNA and hepatitis B surface antigen (HBsAg) levels.
The HBV RNA level significantly correlated with HBcrAg (r=0.629; P<0.001) but not HBsAg levels (P=0.1460). Nonetheless, the HBcrAg level significantly correlated with the HBsAg level (r=0.469; P<0.001). Hepatitis B e antigen (HBeAg)-positive samples showed higher HBV RNA, HBcrAg and HBsAg levels than HBeAg-negative samples did (all P<0.05). Nine patients with HBeAg loss manifested a significantly greater decline in HBV RNA and HBcrAg levels (median 1.84 [25%, 75% percentiles 1.02, 2.12] log
copies/ml, 1.14 [0.62, 2.21] log
U/ml, respectively) compared with those in seven patients without HBeAg loss (0.74 [0.10, 1.08] log
copies/ml and 0.41 [0.21, 0.69] log
U/ml, respectively). Overall, serum HBV RNA, HBcrAg, HBsAg and anti-HBc levels gradually decreased with time during NA treatment. At the end of observation, HBV RNA and HBcrAg reached an undetectable level in 26 and 6 (46% and 11%) patients, respectively.
Monitoring of HBV RNA and HBcrAg levels is useful for NA-treated patients with undetectable HBV DNA. The attainment of HBV RNA undetectability usually occurs prior to HBcrAg undetectability.</description><subject>Adult</subject><subject>Antigens</subject><subject>Antiviral Agents - therapeutic use</subject><subject>Biomarkers</subject><subject>Deoxyribonucleic acid</subject><subject>DNA</subject><subject>Female</subject><subject>Hepatitis</subject><subject>Hepatitis B Antibodies - blood</subject><subject>Hepatitis B Antibodies - immunology</subject><subject>Hepatitis B Core Antigens - blood</subject><subject>Hepatitis B e antigen</subject><subject>Hepatitis B surface antigen</subject><subject>Hepatitis B Surface Antigens - blood</subject><subject>Hepatitis B virus - immunology</subject><subject>Hepatitis B, Chronic - blood</subject><subject>Hepatitis B, Chronic - diagnosis</subject><subject>Hepatitis B, Chronic - drug therapy</subject><subject>Hepatitis B, Chronic - virology</subject><subject>Humans</subject><subject>Interferon</subject><subject>Male</subject><subject>Middle Aged</subject><subject>Nucleoside analogs</subject><subject>Nucleotide analogs</subject><subject>Patients</subject><subject>Ribonucleic acid</subject><subject>RNA</subject><subject>RNA, Viral</subject><subject>Treatment Outcome</subject><subject>Viral Load</subject><issn>1359-6535</issn><issn>2040-2058</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2019</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNpdkctKxDAUhoMoOl7wDSTgQhdWT5KmTZbj4A28Ieq2pE1aK20zJqng1ic3OqMLF4fzc_j4OPAjtEvgmAlOTq5u7hkVsIImFFJIKHCxiiaEcZlknPENtOn9KwAVEmAdbTDghMiUTNDnjR3aYF07NNjW2Bs39vjy9Bk_3E6PYqjctPneftpgNeg4oU3iGXfm3XQetwOeq9CaIXisxx9NZ4cmCcb1eBirzljfanOyiCHGqFCdbUaDw4txav6xjdZq1Xmzs9xb6On87HF2mVzfXVzNptdJxUCGRPBUkTIDUoq0VkJrlWWM5yXLuNZ5qnOoJeEaICtrKnNVVkwJwqtKa6hrydkWOlx4586-jcaHom99ZbpODcaOvqAklSKjkMuI7v9DX-3o4t-RoilhNM8Yi9TBgqqc9d6Zupi7tlfuoyBQfNdSLGuJ5N7SN5a90X_cbw_sC0JLhpw</recordid><startdate>20190101</startdate><enddate>20190101</enddate><creator>Liao, Hao</creator><creator>Liu, Yan</creator><creator>Li, Xiaodong</creator><creator>Wang, Jie</creator><creator>Chen, Xiangmei</creator><creator>Zou, Jun</creator><creator>Li, Qi</creator><creator>Liu, Lujie</creator><creator>Wang, Jun</creator><creator>Huang, Bixia</creator><creator>Lu, Fengmin</creator><creator>Xu, Dongping</creator><general>International Medical Press</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7U9</scope><scope>H94</scope><scope>7X8</scope></search><sort><creationdate>20190101</creationdate><title>Monitoring of serum HBV RNA, HBcrAg, HBsAg and anti-HBc levels in patients during long-term nucleoside/nucleotide analogue therapy</title><author>Liao, Hao ; Liu, Yan ; Li, Xiaodong ; Wang, Jie ; Chen, Xiangmei ; Zou, Jun ; Li, Qi ; Liu, Lujie ; Wang, Jun ; Huang, Bixia ; Lu, Fengmin ; Xu, Dongping</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c309t-854a1b601b84fa8dda66357b365dd74d70f915d006bf297abc3a815ccdd0ff953</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2019</creationdate><topic>Adult</topic><topic>Antigens</topic><topic>Antiviral Agents - therapeutic use</topic><topic>Biomarkers</topic><topic>Deoxyribonucleic acid</topic><topic>DNA</topic><topic>Female</topic><topic>Hepatitis</topic><topic>Hepatitis B Antibodies - blood</topic><topic>Hepatitis B Antibodies - immunology</topic><topic>Hepatitis B Core Antigens - blood</topic><topic>Hepatitis B e antigen</topic><topic>Hepatitis B surface antigen</topic><topic>Hepatitis B Surface Antigens - blood</topic><topic>Hepatitis B virus - immunology</topic><topic>Hepatitis B, Chronic - blood</topic><topic>Hepatitis B, Chronic - diagnosis</topic><topic>Hepatitis B, Chronic - drug therapy</topic><topic>Hepatitis B, Chronic - virology</topic><topic>Humans</topic><topic>Interferon</topic><topic>Male</topic><topic>Middle Aged</topic><topic>Nucleoside analogs</topic><topic>Nucleotide analogs</topic><topic>Patients</topic><topic>Ribonucleic acid</topic><topic>RNA</topic><topic>RNA, Viral</topic><topic>Treatment Outcome</topic><topic>Viral Load</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Liao, Hao</creatorcontrib><creatorcontrib>Liu, Yan</creatorcontrib><creatorcontrib>Li, Xiaodong</creatorcontrib><creatorcontrib>Wang, Jie</creatorcontrib><creatorcontrib>Chen, Xiangmei</creatorcontrib><creatorcontrib>Zou, Jun</creatorcontrib><creatorcontrib>Li, Qi</creatorcontrib><creatorcontrib>Liu, Lujie</creatorcontrib><creatorcontrib>Wang, Jun</creatorcontrib><creatorcontrib>Huang, Bixia</creatorcontrib><creatorcontrib>Lu, Fengmin</creatorcontrib><creatorcontrib>Xu, Dongping</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>Virology and AIDS Abstracts</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>MEDLINE - Academic</collection><jtitle>Antiviral therapy</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Liao, Hao</au><au>Liu, Yan</au><au>Li, Xiaodong</au><au>Wang, Jie</au><au>Chen, Xiangmei</au><au>Zou, Jun</au><au>Li, Qi</au><au>Liu, Lujie</au><au>Wang, Jun</au><au>Huang, Bixia</au><au>Lu, Fengmin</au><au>Xu, Dongping</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Monitoring of serum HBV RNA, HBcrAg, HBsAg and anti-HBc levels in patients during long-term nucleoside/nucleotide analogue therapy</atitle><jtitle>Antiviral therapy</jtitle><addtitle>Antivir Ther</addtitle><date>2019-01-01</date><risdate>2019</risdate><volume>24</volume><issue>2</issue><spage>105</spage><epage>115</epage><pages>105-115</pages><issn>1359-6535</issn><eissn>2040-2058</eissn><abstract>This study was aimed at evaluating the clinical significance of serum HBV RNA, hepatitis B core-related antigen (HBcrAg) and hepatitis B core antibody (anti-HBc) levels in chronic hepatitis B patients with undetectable HBV DNA during nucleoside/nucleotide analogue (NA) treatment.
Fifty-seven patients who received long-term NA treatment of median 5.83 (25%, 75% percentiles 4.67, 7.75) years were enrolled, and 285 serum samples at five time points for each patient were quantitatively analysed for the three serum markers together with serum HBV DNA and hepatitis B surface antigen (HBsAg) levels.
The HBV RNA level significantly correlated with HBcrAg (r=0.629; P<0.001) but not HBsAg levels (P=0.1460). Nonetheless, the HBcrAg level significantly correlated with the HBsAg level (r=0.469; P<0.001). Hepatitis B e antigen (HBeAg)-positive samples showed higher HBV RNA, HBcrAg and HBsAg levels than HBeAg-negative samples did (all P<0.05). Nine patients with HBeAg loss manifested a significantly greater decline in HBV RNA and HBcrAg levels (median 1.84 [25%, 75% percentiles 1.02, 2.12] log
copies/ml, 1.14 [0.62, 2.21] log
U/ml, respectively) compared with those in seven patients without HBeAg loss (0.74 [0.10, 1.08] log
copies/ml and 0.41 [0.21, 0.69] log
U/ml, respectively). Overall, serum HBV RNA, HBcrAg, HBsAg and anti-HBc levels gradually decreased with time during NA treatment. At the end of observation, HBV RNA and HBcrAg reached an undetectable level in 26 and 6 (46% and 11%) patients, respectively.
Monitoring of HBV RNA and HBcrAg levels is useful for NA-treated patients with undetectable HBV DNA. The attainment of HBV RNA undetectability usually occurs prior to HBcrAg undetectability.</abstract><cop>England</cop><pub>International Medical Press</pub><pmid>30511941</pmid><doi>10.3851/IMP3280</doi><tpages>11</tpages></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 1359-6535 |
| ispartof | Antiviral therapy, 2019-01, Vol.24 (2), p.105-115 |
| issn | 1359-6535 2040-2058 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_2149862079 |
| source | MEDLINE; Sage Journals GOLD Open Access 2024; Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals |
| subjects | Adult Antigens Antiviral Agents - therapeutic use Biomarkers Deoxyribonucleic acid DNA Female Hepatitis Hepatitis B Antibodies - blood Hepatitis B Antibodies - immunology Hepatitis B Core Antigens - blood Hepatitis B e antigen Hepatitis B surface antigen Hepatitis B Surface Antigens - blood Hepatitis B virus - immunology Hepatitis B, Chronic - blood Hepatitis B, Chronic - diagnosis Hepatitis B, Chronic - drug therapy Hepatitis B, Chronic - virology Humans Interferon Male Middle Aged Nucleoside analogs Nucleotide analogs Patients Ribonucleic acid RNA RNA, Viral Treatment Outcome Viral Load |
| title | Monitoring of serum HBV RNA, HBcrAg, HBsAg and anti-HBc levels in patients during long-term nucleoside/nucleotide analogue therapy |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-02T02%3A26%3A32IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Monitoring%20of%20serum%20HBV%20RNA,%20HBcrAg,%20HBsAg%20and%20anti-HBc%20levels%20in%20patients%20during%20long-term%20nucleoside/nucleotide%20analogue%20therapy&rft.jtitle=Antiviral%20therapy&rft.au=Liao,%20Hao&rft.date=2019-01-01&rft.volume=24&rft.issue=2&rft.spage=105&rft.epage=115&rft.pages=105-115&rft.issn=1359-6535&rft.eissn=2040-2058&rft_id=info:doi/10.3851/IMP3280&rft_dat=%3Cproquest_cross%3E2241327633%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2241327633&rft_id=info:pmid/30511941&rfr_iscdi=true |